275 related articles for article (PubMed ID: 28051882)
1. Are sigma modulators an effective opportunity for cancer treatment? A patent overview (1996-2016).
Collina S; Bignardi E; Rui M; Rossi D; Gaggeri R; Zamagni A; Cortesi M; Tesei A
Expert Opin Ther Pat; 2017 May; 27(5):565-578. PubMed ID: 28051882
[TBL] [Abstract][Full Text] [Related]
2. Sigma receptor modulators: a patent review.
Collina S; Gaggeri R; Marra A; Bassi A; Negrinotti S; Negri F; Rossi D
Expert Opin Ther Pat; 2013 May; 23(5):597-613. PubMed ID: 23387851
[TBL] [Abstract][Full Text] [Related]
3. Gaining in pan-affinity towards sigma 1 and sigma 2 receptors. SAR studies on arylalkylamines.
Rossi D; Rui M; Di Giacomo M; Schepmann D; Wünsch B; Monteleone S; Liedl KR; Collina S
Bioorg Med Chem; 2017 Jan; 25(1):11-19. PubMed ID: 27838169
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents.
Rui M; Rossi D; Marra A; Paolillo M; Schinelli S; Curti D; Tesei A; Cortesi M; Zamagni A; Laurini E; Pricl S; Schepmann D; Wűnsch B; Urban E; Pace V; Collina S
Eur J Med Chem; 2016 Nov; 124():649-665. PubMed ID: 27614411
[TBL] [Abstract][Full Text] [Related]
5. Sigma Receptors as Endoplasmic Reticulum Stress "Gatekeepers" and their Modulators as Emerging New Weapons in the Fight Against Cancer.
Tesei A; Cortesi M; Zamagni A; Arienti C; Pignatta S; Zanoni M; Paolillo M; Curti D; Rui M; Rossi D; Collina S
Front Pharmacol; 2018; 9():711. PubMed ID: 30042674
[TBL] [Abstract][Full Text] [Related]
6. MYC modulators in cancer: a patent review.
Wang XN; Su XX; Cheng SQ; Sun ZY; Huang ZS; Ou TM
Expert Opin Ther Pat; 2019 May; 29(5):353-367. PubMed ID: 31068032
[TBL] [Abstract][Full Text] [Related]
7. The sigma-2 (σ-2) receptor: a review of recent patent applications: 2013-2018.
Blass BE; Rogers JP
Expert Opin Ther Pat; 2018 Sep; 28(9):655-663. PubMed ID: 30185082
[TBL] [Abstract][Full Text] [Related]
8. Marine Derived Anticancer Drugs Targeting Microtubule.
De O; Chatterji BP
Recent Pat Anticancer Drug Discov; 2017; 12(2):102-127. PubMed ID: 28067173
[TBL] [Abstract][Full Text] [Related]
9. A FGFR1 inhibitor patent review: progress since 2010.
Yu T; Yang Y; Liu Y; Zhang Y; Xu H; Li M; Ponnusamy M; Wang K; Wang JX; Li PF
Expert Opin Ther Pat; 2017 Apr; 27(4):439-454. PubMed ID: 27976968
[TBL] [Abstract][Full Text] [Related]
10. Tubulin inhibitors: a patent review.
Liu YM; Chen HL; Lee HY; Liou JP
Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
[TBL] [Abstract][Full Text] [Related]
11. BET inhibitors in cancer therapeutics: a patent review.
Ghoshal A; Yugandhar D; Srivastava AK
Expert Opin Ther Pat; 2016; 26(4):505-22. PubMed ID: 26924192
[TBL] [Abstract][Full Text] [Related]
12. Dendrimer and cancer: a patent review (2006-present).
Cai X; Hu J; Xiao J; Cheng Y
Expert Opin Ther Pat; 2013 Apr; 23(4):515-29. PubMed ID: 23339480
[TBL] [Abstract][Full Text] [Related]
13. Na+/K+-ATPase and cancer.
Mijatovic T; Dufrasne F; Kiss R
Pharm Pat Anal; 2012 Mar; 1(1):91-106. PubMed ID: 24236716
[TBL] [Abstract][Full Text] [Related]
14. Potential applications for sigma receptor ligands in cancer diagnosis and therapy.
van Waarde A; Rybczynska AA; Ramakrishnan NK; Ishiwata K; Elsinga PH; Dierckx RA
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2703-14. PubMed ID: 25173780
[TBL] [Abstract][Full Text] [Related]
15. Anticancer patent landscape and technology assessment of Indian public-funded research institutes and organizations.
Dara A; Sangamwar AT
Expert Opin Ther Pat; 2014 Aug; 24(8):893-912. PubMed ID: 24898985
[TBL] [Abstract][Full Text] [Related]
16. A patent review of anticancer glucocorticoid receptor modulators (2014-present).
Lucafò M; Franzin M; Decorti G; Stocco G
Expert Opin Ther Pat; 2020 May; 30(5):313-324. PubMed ID: 32148111
[No Abstract] [Full Text] [Related]
17. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
18. S2R(Pgrmc1): the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling.
Ahmed IS; Chamberlain C; Craven RJ
Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):361-70. PubMed ID: 22292588
[TBL] [Abstract][Full Text] [Related]
19. Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010).
Marzaro G; Guiotto A; Chilin A
Expert Opin Ther Pat; 2012 Mar; 22(3):223-52. PubMed ID: 22404097
[TBL] [Abstract][Full Text] [Related]
20. Quinazoline derivatives as anticancer drugs: a patent review (2011 - present).
Ravez S; Castillo-Aguilera O; Depreux P; Goossens L
Expert Opin Ther Pat; 2015 Jul; 25(7):789-804. PubMed ID: 25910402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
